Actinium Pharmaceuticals, Inc. (delaware) · AMEX:ATNM

Actinium Pharmaceuticals, Inc. (delaware) — Actinium Pharmaceuticals — TCT Late Breaking Oral Presentation 2019

12 slides from Actinium Pharmaceuticals, Inc. (delaware)'s conference presentation, 2019

  1. Slide 1: Novel Re-Induction and Anti-CD45 Targeted Conditioning with Iomab-B in R/R AML

    Strictly Private & Confidential Novel Re-Induction and Anti-CD45 Targeted Conditioning with Iodine (131I) Apamistamab [Iomab-B] Yields Encouraging Results in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): Safety and Feasibility Data from the Prospective, Randomi

  2. Slide 2: Iodine (131I) apamistamab [Iomab-B] CD45 Targeted Conditioning

    Strictly Private & Confidential Iodine (131I) apamistamab [Iomab-B] CD45 Targeted Conditioning ♦ Iodine (131I) apamistamab [Iomab-B] is a murine anti-CD45 targeted therapy that was developed at the Fred Hutchinson Cancer Research Center ♦ Encouraging Phase II data led to the ongoing SIERRA Phase III

  3. Slide 3: Iomab-B Potential – Background and Rationale

    Strictly Private & Confidential Iomab-B Potential – Background and Rationale 1) Biol Blood Marrow Transplant 15 :1431-1438 (2009), MD Anderson outcomes analysis. (Chemo + BMT n=19) (Salvage Chemo n = 95) 2) Iomab-B BMT: Blood 114:5444-5453 (2009) and additional data on file Pagel et. al. (n=36) • Co

  4. Slide 4: SIERRA Phase 3 Trial Design

    Strictly Private & Confidential SIERRA Phase 3 Trial Design Study Design (N=150) Primary End-point: Durable Complete Response Rate (dCR): morphologic CR lasting ≥180 days Secondary End-point: 1-year Overall Survival Key Eligibility Criteria: Active, relapsed or refractory AML defined as: • Bone marr

  5. Slide 5: SIERRA Iomab-B Treatment Schedule

    Strictly Private & Confidential SIERRA Iomab-B Treatment Schedule Internal Use Only Iomab-B Specific Standard Transplant Procedure ~7 days ~12 days Dosimetry Therapy Dose RIC HCT Iomab-B Iomab-B FLU TBI (~10-20 mCi) (24 Gy to liver, mean~600mCi) 30 mg/m2/d 200 cGy -12 to HCT -4 -3 -2 -1 0 Imaging Im

  6. Slide 6: SIERRA Trial: Demographics Highlights

    Strictly Private & Confidential SIERRA Trial: Demographics Highlights • ASH presentation based on safety data from first 25% of patients enrolled. Updated results for this cohort being presented at today’s session • Additional protocol defined safety updates at 50% and 75% of planned enrollment Ongo

  7. Slide 7: Novel Re-induction and Targeted Conditioning Therapy Yields Encouraging Results

    Strictly Private & Confidential Novel Re-induction and Targeted Conditioning Therapy Yields Encouraging Results in Active, Relapsed or Refractory AML Randomized to Randomized to Conventional Care (N=19) Iomab-B and Achieved CR Did not achieve CR transplanted and received standard Crossed over to Iom

  8. Slide 8: Non–Heme Grade 3 or 4 AEs (>10% of patients)

    Non–Heme Grade 3 or 4 AEs (>10% of patients) Strictly Private & Confidential Up to a 100-days post transplant or till crossover assessment* Randomized to Iomab-B Randomized to Conventional Total Adverse Event Study Arm (N=19) Care Arm (N=19) (N=38) (%) (%) (%) Febrile Neutropenia 4 (21.1) 9 (47.4) 1

  9. Slide 9: Non–Heme Grade 3 or 4 AEs in Transplanted Patients

    Non–Heme Grade 3 or 4 AEs in Transplanted Patients Strictly Private & Confidential Up to a 100-days post transplant Randomized to Iomab-B Crossed over to Iomab-B Adverse Event Study Arm arm and transplanted (>10% of total patients) N=19 (%) N=10 (%) Febrile Neutropenia 4 (21) 4 (40) Stomatitis 3 (16

  10. Slide 10: 100 Days Non-Relapse Mortality in Transplanted Patients

    Strictly Private & Confidential 100 Days Non-Relapse Mortality in Transplanted Patients Randomized to Conventional Care (N=19) Randomized to Iomab-B Achieved CR Did not achieve CR and transplanted and received standard of Crossed over to Iomab-B arm care transplant and transplanted (N=18) (N=4) (N=1

  11. Slide 11: Conclusions

    Strictly Private & Confidential Conclusions ♦ SIERRA is the only randomized, on-going Phase III clinical trial that offers transplant option to patients 55 years or older with active, relapsed or refractory AML − Historically under-served population − Dismal survival prognosis − Limited options for

  12. Slide 12: Acknowledgements and Currently Active Sites

    Strictly Private & Confidential Acknowledgements and Currently Active Sites Actinium 12 Pharmaceuticals

Actinium Pharmaceuticals — TCT Late Breaking Oral Presentation 2019 on 6ix